ReviewNeurobiology of disease2026
Beyond total BDNF: The proBDNF/mBDNF balance in substance use disorders.
Review in Neurobiology of disease, 2026. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Not yet cited in PubMed.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
0 citing papers in PubMed.
No citing paper in PubMed yet.
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
6 authors.
Funding
Abstract
Brain-derived neurotrophic factor (BDNF) is a central regulator of synaptic plasticity, neuronal survival, and reward circuitry, all of which have been implicated in substance use disorders (SUDs). While prior research has focused on total BDNF levels, emerging evidence highlights the importance of its two major isoforms, proBDNF and mature BDNF (mBDNF), which exert opposing effects through differential receptor activation. ProBDNF promotes synaptic weakening and neuronal apoptosis, while mBDNF supports synaptic strengthening and neuronal survival. Environmental exposures, such as substances of abuse, may shift the proBDNF/mBDNF balance and thereby influence addiction-related neuroplasticity. This review synthesizes evidence highlighting the need to resolve BDNF isoforms, suggesting that the proBDNF/mBDNF ratio may provide mechanistic insight beyond total BDNF alone in addiction neurobiology. We examine BDNF isoform changes following exposure to alcohol, stimulants, and opioids, integrating clinical and preclinical evidence across stages of addiction (acute exposure, chronic use, withdrawal, and abstinence) and brain regions. Collectively, the evidence supports a model in which the proBDNF/mBDNF balance reflects region-specific neurobiological adaptations across stages of addiction. Future isoform-resolved longitudinal clinical studies, together with mechanistic animal and cellular models, may clarify causal relationships and identify opportunities for therapeutic modulation of BDNF signaling in SUDs.
Indexed as
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.